Related Experiment Videos
Atherogenic dyslipidemia: lipoprotein abnormalities and implications for therapy
1Department of Clinical Nutrition, University of Texas Southwestern Medical Center, Dallas 75235-9052.
The American Journal of Cardiology
|February 23, 1995
Summary
Atherogenic dyslipidemia, a combination of cholesterol and triglyceride abnormalities, significantly increases coronary artery disease risk. Management involves lifestyle changes and medications like statins and fibric acids to improve lipid profiles.
Area of Science:
- Cardiology
- Metabolic Disorders
- Lipidology
Background:
- Atherogenic dyslipidemia is characterized by high triglycerides, low HDL, and small, dense LDL particles.
- This lipid profile is a significant risk factor for premature coronary artery disease (CAD).
- The total cholesterol to HDL cholesterol ratio is a key predictor of risk in dyslipidemic patients.
Purpose of the Study:
- To outline the characteristics of atherogenic dyslipidemia.
- To discuss its association with coronary artery disease.
- To review current therapeutic strategies for managing this condition.
Main Methods:
- Review of existing literature on atherogenic dyslipidemia and its management.
- Analysis of the components of atherogenic dyslipidemia and their individual contributions to CAD risk.
- Evaluation of therapeutic interventions including lifestyle modifications and pharmacotherapy.
Main Results:
- Atherogenic dyslipidemia combines high total cholesterol, high triglycerides, low HDL, and small, dense LDL.
- The total cholesterol/HDL ratio is a powerful predictor of CAD risk.
- Therapies include diet, exercise, and medications such as nicotinic acid, fibric acids, and statins.
Conclusions:
- Effective management of atherogenic dyslipidemia requires a multi-faceted approach.
- Lifestyle modifications are foundational, often supplemented by pharmacotherapy.
- Combination drug therapy can optimize lipid profiles and reduce cardiovascular risk.